CEO exercised or converted 200K ROIV derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Jun 24, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Jun 27, 2026
CEOOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001635088-26-000071
Filed / recordedJun 27, 2026, 2:13 AM UTCAdded to OQROOct 6, 2026, 8:46 PM UTC Data qualityVerified: identifiers matched exactly IssuerRoivant Sciences Ltd. Reporting personEric Venker Officer titlePresident & Immunovant CEO SecurityStock Option (Right to Buy) TableDerivative (Table II) Transaction dateJun 24, 2026 Acquired / disposedDisposed (D) Shares owned after4,244,834 Footnotes from the filing
- Reflects an award of stock options to purchase Common Shares that is fully vested.
Around the same time
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.